Atrium Therapeutics, Inc. (RNA)
NASDAQ: RNA · Real-Time Price · USD
12.70
+0.33 (2.67%)
At close: Jun 15, 2026, 4:00 PM EDT
12.75
+0.05 (0.39%)
After-hours: Jun 15, 2026, 4:10 PM EDT
Atrium Therapeutics Stock Forecast
Stock Price Forecast
The 2 analysts with 12-month price forecasts for Atrium Therapeutics stock have an average target of $25, which predicts a 96.85% increase from the current stock price of 12.7.
Price Target: $25 (+96.85%)
Analyst Consensus: Strong Buy
* Price targets were last updated on May 15, 2026.
Analyst Ratings
The average analyst rating for Atrium Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Mar '26 | May '26 |
|---|---|---|
| Strong Buy | 1 | 2 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
| Total | 1 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Leerink Partners | Leerink Partners | Buy Initiates $25 | Buy | Initiates | $25 | +96.85% | May 15, 2026 |
| Wells Fargo | Wells Fargo | Buy Initiates $25 | Buy | Initiates | $25 | +96.85% | Mar 10, 2026 |
Financial Forecast
Revenue This Year
22.60M
from 18.62M
Increased by 21.39%
Revenue Next Year
4.00M
from 22.60M
Decreased by -82.30%
EPS This Year
n/a
EPS Next Year
n/a
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 25.6M | ||
| Avg | 22.6M | ||
| Low | 19.6M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 37.5% | ||
| Avg | 21.4% | ||
| Low | 5.3% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | ||
| Avg | - | ||
| Low | - |
EPS Growth
| EPS Growth | 2027 | 2028 |
|---|---|---|
| High | - | |
| Avg | - | |
| Low | - |